Likewise, these data demonstrate a dose-dependent response and profound CD4CAR NK-92 cell anti-tumor activity in a cell line and patient sample setting for both adult and pediatric CD4+ T cell leukemias and lymphomas. The gene discussed is CD4; the disease is neoplasm.